On December 11, 2025, BioCryst Pharmaceuticals Inc (BCRX) disclosed a leadership transition on its Board of Directors. The 8-K filing disclosed the retirement of one director and the election of a new Board Chair, effective at the company's 2026 annual meeting of stockholders.

According to the filing, Nancy J. Hutson, Ph.D., announced her retirement from the Board of Directors of BioCryst Pharmaceuticals, Inc. The company reported the departure under Item 5.02 of the 8-K form, which covers departures of directors or principal officers.

The Board of Directors elected Vincent J. Milano as the next Chair of the Board, according to the same filing. The transition is scheduled to take effect at the company's annual meeting of stockholders in 2026, as stated in the document.